We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...
The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.
Somewhere between 35-80% of people with PMOS experience insulin resistance, making weight management important.” ...
Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 ...
BioInvent International AB (publ) ( BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors May 27, 2026 8:00 AM EDT Good morning, and welcome to the BioInvent ...
Dr. Jaclyn Smeaton, ND A clinical review of the landmark renaming of PCOS to PMOS and why this shift reframes the condition ...
Dr. Emmalyn Pratt, ND Subheadline Two fertility case reports exploring the potential role of ovarian platelet-rich plasma ...
An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In ...
Adding chiauranib to weekly paclitaxel improves PFS, but not OS, in patients with platinum-resistant or refractory ovarian cancer.
While the number of eggs that women are born with is genetically predetermined, there are potential ways to optimize ovarian longevity and become an ova-achiever.
For decades, the 'PCOS' label has misdirected care and ignored the metabolic, mental, and cardiovascular struggles of those affected ...
Appointments enhance commercialization readiness as Zentalis advances registrational program for azenosertib in Cyclin-E1 positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results